Product Monograph - Odan-Indomethacin
RECENT MAJOR LABEL CHANGES
| 2 CONTRAINDICATIONS | 02/2022 |
| 3 SERIOUSWARNINGSAND PRECAUTIONSBOX | 02/2022 |
| 7 WARNINGSAND PRECAUTIONS, Cardiovascular | 02/2022 |
| 7 WARNINGSAND PRECAUTIONS, Monitoring and Laboratory Tests | 02/2022 |
| 7 WARNINGSAND PRECAUTIONS, Skin | 02/2022 |
| 7 WARNINGSAND PRECAUTIONS, 7.1 Special Populations | 02/2022 |
TABLE OF CONTENTS
Sections or subsections that are not applicable at the time of authorization are not listed.
RECENT MAJOR LABEL CHANGES .................................................................................... 2
TABLE OF CONTENTS ....................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4
1 INDICATIONS.............................................................................................................4
1.1 Pediatrics ...................................................................................................... 5 1.2 Geriatrics ...................................................................................................... 5 2 CONTRAINDICATIONS ................................................................................................5
3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................ 6
4 DOSAGE AND ADMINISTRATION ................................................................................7
4.1 Dosing considerations .................................................................................. 7 4.2 Recommended Dose and Dosage Adjustment ............................................ 8 4.4 Administration ............................................................................................. 8 4.5 Missed Dose ................................................................................................. 8 5 OVERDOSAGE ...........................................................................................................8
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .................................8
7 WARNINGS AND PRECAUTIONS .................................................................................9
7.1 Special Populations .................................................................................... 16
7.1.1 Pregnant Women ........................................................................... 16 7.1.2 Breast-feeding ................................................................................ 17 7.1.3 Pediatrics ........................................................................................ 17 7.1.4 Geriatrics ........................................................................................ 17 8 ADVERSE REACTIONS .............................................................................................. 18
8.1 Adverse Reaction Overview ....................................................................... 18 8.2 Clinical Trial Adverse Reactions ................................................................. 18 8.3 Less Common Clinical Trial Adverse Reactions .......................................... 19 8.5 Post-Market Adverse Reactions ................................................................. 20 9 DRUG INTERACTIONS .................................................................................................. 20
9.1 Serious Drug Interactions ........................................................................... 20 9.3 Drug-Behaviour Interactions ...................................................................... 20 9.4 Drug-Drug Interactions .............................................................................. 20
9.5 Drug-Food Interactions .................................................................................... 25 9.6 Drug-Herb Interactions .................................................................................... 25 9.7 Drug-Laboratory Test Interactions ................................................................... 25 10 CLINICAL PHARMACOLOGY ....................................................................................... 25
10.1 Mechanism of Action ................................................................................. 25 10.2 Pharmacodynamics .................................................................................... 25 10.3 Pharmacokinetics ....................................................................................... 26 11 STORAGE, STABILITY AND DISPOSAL ...................................................................... 28
12 SPECIAL HANDLING INSTRUCTIONS ........................................................................ 28
PART II: SCIENTIFIC INFORMATION ............................................................................. 29
13 PHARMACEUTICAL INFORMATION ......................................................................... 29
14 CLINICAL TRIALS ........................................................................................................ 29
14.3 Comparative Bioavailability Studies ........................................................... 29 15 MICROBIOLOGY .................................................................................................... 31
16 NON-CLINICAL TOXICOLOGY ................................................................................. 31
PATIENT MEDICATION INFORMATION ........................................................................ 32
PART I: HEALTH PROFESSIONAL INFORMATION
1 INDICATIONS
ODAN-INDOMETHACIN (indomethacin suppositories) is indicated for the symptomatic treatment of:
- Selected cases of rheumatoid arthritis
- Ankylosing (rheumatoid) spondylitis
- Gout
- Selected cases of severe osteoarthritis, including degenerative disease of the hip
Indomethacin is not a simple analgesic, and its use should be limited to those conditions listed below, particularly those cases not responding to conservative measures.
In these conditions, indomethacin may on occasion replace other commonly used agents such as corticosteroids, salicylates, phenylbutazone-like compounds, and colchicine.
Indomethacin suppositories are for those patients in whom rectal administration is preferred.
Rheumatoid Arthritis
Indomethacin may be used singly or in combination with other agents. However, it should not be used as a drug of first choice because of the adverse reactions that may occur with its use.
Best results (relief of pain, tenderness, swelling and stiffness) have been obtained in the acute episodes of the disease. However, in many patients with chronic rheumatoid arthritis, indomethacin produces a significant lessening of pain and stiffness within 48 hours. In other patients, treatment must be continued longer before significant subjective relief or objective evidence of decreased joint swelling and tenderness occur. In some cases of chronic rheumatoid arthritis, it may be necessary to continue treatment for at least a month before concluding that it has not produced significant benefit. Use of indomethacin may enable reduction of steroid dosage in patients receiving corticosteroids. In such instances, the steroid dosage should be reduced slowly.
Ankylosing (Rheumatoid) Spondylitis
Indomethacin frequently produces marked relief of pain and improved motion of the spine within 3 to 10 days.
Osteoarthritis
Indomethacin should be used in those cases of severe osteoarthritis which do not respond to treatment with such other drugs as the salicylates. In many cases prompt relief of pain is obtained.
Degenerative Joint Disease (Osteoarthritis) of the Hip
Indomethacin has provided relief of pain and increased range of motion in patients with degenerative joint disease of the hip.
Gout
In acute attacks of gout, the response to indomethacin is usually rapid and often dramatic. Marked reduction of pain may be obtained within 2 to 4 hours. Tenderness and heat subside within 24 to 36 hours, and swelling decreases over a 3 to 5 day period.
For patients with an increased risk of developing CV and/or GI adverse events, other management strategies that do NOT include the use of NSAIDs should be considered first. (See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS)
Use of ODAN-INDOMETHACIN should be limited to the lowest effective dose for the shortest possible duration of treatment in order to minimize the potential risk for cardiovascular or gastrointestinal adverse events. (See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS)
ODAN-INDOMETHACIN, as a NSAID, does NOT treat clinical disease or prevent its progression.
ODAN-INDOMETHACIN, as a NSAID, only relieves symptoms and decreases inflammation for as long as the patient continues to take it.
1.1 Pediatrics
Pediatrics (<15 years of age): The drug should not be prescribed for children because safe conditions for use have not been established in those 15 years and younger. In a few cases of severe juvenile rheumatoid arthritis, where indomethacin was given along with other drugs, severe reactions, including fatalities, were reported. See 2 CONTRAINDICATIONS.
1.2 Geriatrics
Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Since advancing years appear to increase the possibility of adverse reactions, indomethacin should be used with greater care in the elderly. See 7.1.4 Geriatrics and 4 DOSAGE AND ADMINISTRATION.
2 CONTRAINDICATIONS
ODAN-INDOMETHACIN is contraindicated in:
the peri-operative setting of coronary artery bypass graft surgery (CABG).
Although indomethacin has NOT been studied in this patient population, a selective COX-2 inhibitor NSAID studied in such a setting has led to an increased incidence of cardiovascular/thromboembolic events, deep surgical infections and sternal wound complications.
- the third trimester of pregnancy, because of risk of premature closure of the ductus arteriosus, and prolonged parturition
- women who are breast-feeding, because of the potential for serious adverse reactions in nursing infants
- severe uncontrolled heart failure
- patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
history of asthma, urticaria, or allergic-type reactions after taking ASA or other NSAIDs (i.e.
complete or partial syndrome of ASA-intolerance - rhinosinusitis, urticaria/ angioedema, nasal polyps, asthma). Fatal anaphylactoid reactions have occurred in such individuals. Individuals with the above medical problems are at risk of a severe reaction even if they have taken NSAIDs in the past without any adverse reaction. The potential for cross-reactivity between different NSAIDs must be kept in mind (see 7 WARNINGS AND PRECAUTIONS – Hypersensitivity Reactions
- Anaphylactoid Reactions).
- active gastric / duodenal / peptic ulcer, active GI bleeding, a history of recurrent ulceration or active inflammatory disease of the gastrointestinal system
- cerebrovascular bleeding or other bleeding disorders
- inflammatory bowel disease
- severe liver impairment or active liver disease
- severe renal impairment (creatinine clearance <30 mL/min or 0.5 mL/sec) or deteriorating renal disease (individuals with lesser degrees of renal impairment are at risk of deterioration of their renal function when prescribed NSAIDs and must be monitored) (see 7 WARNINGS AND PRECAUTIONS - Renal).
known hyperkalemia (see 7 WARNINGS AND PRECAUTIONS - Renal - Fluid and
Electrolyte Balance).
- children and adolescents less than 15 years of age
- For use with other NSAIDs because of the absence of any evidence demonstrating synergistic benefits and the potential for additive side effects.
- In subjects with a recent history of rectal bleeding or proctitis.
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
Risk of Cardiovascular (CV) Adverse Events: Ischemic Heart Disease, Cerebrovascular Disease,
Congestive Heart Failure (NYHA II-IV)
(See 7 WARNINGS AND PRECAUTIONS - Cardiovascular).
ODAN-INDOMETHACIN isa non-steroidal anti-inflammatory drug (NSAID). Use of some NSAIDs is associated with an increased incidence of cardiovascular adverse events (such as myocardial infarction, stroke or thrombotic events) which can be fatal. The risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Caution should be exercised in prescribing ODAN-INDOMETHACIN to any patient with ischemic heart disease (including but NOT limited to acute myocardial infarction, history of myocardial infarction and/or angina), cerebrovascular disease (including but NOT limited to stroke, cerebrovascular accident, transient ischemic attacks and/or amaurosis fugax) and/or congestive heart failure (NYHA II- IV).
Use of NSAIDs, such as ODAN-INDOMETHACIN, can promote sodium retention in a dose-dependent manner, through a renal mechanism, which can result in increased blood pressure and/or exacerbation of congestive heart failure. (see also 7 WARNINGS AND PRECAUTIONS - Renal - Fluid and Electrolyte Balance)
Randomized clinical trials with indomethacin have not been designed to detect differences in cardiovascular events in a chronic setting. Therefore, caution should be exercised when prescribing ODAN-INDOMETHACIN.
Risk of Gastrointestinal (GI) Adverse Events
(see 7 WARNINGS AND PRECAUTIONS - Gastrointestinal)
Use of NSAIDs, such as ODAN-INDOMETHACIN, is associated with an increased incidence of gastrointestinal adverse events (such as peptic/duodenal ulceration, perforation, obstruction and gastrointestinal bleeding)
- Risk in Pregnancy:
Caution should be exercised in prescribing ODAN-INDOMETHACIN during the first and second trimesters of pregnancy. Use of NSAIDs at approximately 20 weeks of gestation or later may cause fetal renal dysfunction leading to oligohydramnios and neonatal renal impairment or failure (see 7 WARNINGS AND PRECAUTIONS). ODAN-INDOMETHACIN is contraindicated for use during the third trimester because of risk of premature closure of the ductus arteriosus and uterine inertia (prolonged parturition) (see 2 CONTRAINDICATIONS).
4 DOSAGE AND ADMINISTRATION
4.1 Dosing considerations
Carefully consider the potential benefits and risks of ODAN-INDOMETHACIN and other treatment options before deciding to use ODAN-INDOMETHACIN. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.
Since advancing years appear to increase the possibility of adverse reactions, indomethacin should be used with greater care in the elderly.
Patient Monitoring Guidelines: Routine monitoring of liver function is recommended.
Indications for Discontinuing Treatment:
- If ulceration is suspected or confirmed or if GI bleeding occurs.
- Urinary symptoms (such as bladder pain, dysuria, urinary frequency), hematuria or cystitis.
- If abnormal liver tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g. eosinophilia, rash, etc.)
- Blurred and/or diminished vision.
- If headache persists despite dosage reduction therapy.
4.2 Recommended Dose and Dosage Adjustment
Use of ODAN-INDOMETHACIN should be limited to the lowest effective dose for the shortest possible duration of treatment in order to minimize the potential risk for cardiovascular or gastrointestinal adverse events.
The recommended dosage of indomethacin suppositories is 100 to 200 mg daily and should be individually adjusted to the patient's response and tolerance. Daily doses of 100 mg can be given as 50 mg twice daily or as 100 mg at night. Doses higher than 100 mg must be given on a twice daily schedule.
Geriatrics (>65 years of age):
Consideration should be given to a starting dose lower than the one usually recommended, with individual adjustment when necessary and under close supervision (see 7.1.4 Geriatrics).
Renalimpairment:
A lower daily dose should be considered in patients with mild and moderate renal impairment (see 7 WARNINGS AND PRECAUTIONS - Renal - Fluid and Electrolyte Balance).
4.4 Administration
For combined administration of indomethacin capsules and suppositories, the total daily dose of indomethacin should not exceed 200 mg.
4.5 Missed Dose
If a dose of ODAN-INDOMETHACIN suppositories is missed and remembered within an hour or so, it should be taken right away. Then go back to the regular dosing schedule.
5 OVERDOSAGE
Relatively little experience is available recording overdosage with indomethacin. Nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy might be observed. There have been reports of paresthesia, numbness, and convulsions. Signs of gastrointestinal hemorrhage could appear but have not been reported following the acute ingestion of large amounts of indomethacin accidentally or intentionally.
Treatment of Overdosage: Symptomatic and supportive. Empty the stomach as quickly as possible by emesis or lavage if the ingestion is recent. Depending on the condition of the patients, close medical observation and nursing care may be required. The patient should be followed for several days because gastrointestinal ulceration and hemorrhage have been reported as adverse reactions of indomethacin. Use of antacids may be helpful. Indomethacin is not dialyzable.
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
Table 1 – Dosage Forms, Strengths, Composition and Packaging
For management of a suspected drug overdose, contact your regional poison control centre.
| Route of | Dosage Form / | |
| Non-medicinal Ingredients | ||
| Administration | Strength/Composition | |
| Rectal | 50 mg and 100 mg Suppository | Suppocire |
Each white opaque suppository contains either 50 mg or 100 mg of indomethacin. Available in boxes of 30, individually wrapped in plastic foil shells.
7 WARNINGS AND PRECAUTIONS
Please see 3 SERIOUS WARNINGSAND PRECAUTIONSBOX
General
Frail or debilitated patients may tolerate side effects less well and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse event, the lowest effective dose should be used for the shortest possible duration. As with other NSAIDs, caution should be used in the treatment of elderly patients who are more likely to be suffering from impaired renal, hepatic or cardiac function. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.
ODAN-INDOMETHACIN is NOT recommended for use with other NSAIDs, with the exception of low-dose ASA for cardiovascular prophylaxis, because of the absence of any evidence demonstrating synergistic benefits and the potential for additive adverse reactions. See 9 DRUG INTERACTIONS.
Cardiovascular
ODAN-INDOMETHACIN is a non-steroidal anti-inflammatory drug (NSAID). Use of some NSAIDs is associated with an increased incidence of cardiovascular adverse events (such as myocardial infarction, stroke or thrombotic events) which can be fatal. The risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Caution should be exercised in prescribing ODAN-INDOMETHACIN to patients with risk factors for cardiovascular disease, cerebrovascular disease or renal disease, such as any of the following (NOT an exhaustive list)
- Hypertension
- Dyslipidemia / Hyperlipidemia
- Diabetes Mellitus
- Congestive Heart Failure (NYHA I)
- Coronary Artery Disease (Atherosclerosis)
- Peripheral Arterial Disease
- Smoking
- Creatinine Clearance < 60 mL/min or 1 mL/sec
Use of NSAIDs, such as ODAN-INDOMETHACIN, can lead to new hypertension or can worsen pre-existing hypertension, either of which may increase the risk of cardiovascular events as described above.
Thus blood pressure should be monitored regularly. Consideration should be given to discontinuing ODAN-INDOMETHACIN should hypertension either develop or worsen with its use.
Use of NSAIDs, such as ODAN-INDOMETHACIN, can induce fluid retention and edema, and may exacerbate congestive heart failure, through a renally-mediated mechanism. (See 7 WARNINGS AND PRECAUTIONS - Renal - Fluid and Electrolyte Balance).
For patients with a high risk of developing an adverse CV event, other management strategies that do NOT include the use of NSAIDs should be considered first. To minimize the potential risk for an adverse CV event, the lowest effective dose should be used for the shortest possible duration.
Endocrine and Metabolism
Corticosteroids: ODAN-INDOMETHACIN is NOT a substitute for corticosteroids. It does NOT treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid-responsive illness. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. See 9 DRUG INTERACTIONS
Fluid and Electrolyte Balance
See 7 WARNINGS AND PRECAUTIONS - Renal.
Gastrointestinal (GI)
Serious GI toxicity (sometimes fatal), such as peptic / duodenal ulceration, inflammation, perforation, obstruction and gastrointestinal bleeding, can occur at any time, with or without warning symptoms, in patients treated with NSAIDs, such as ODAN-INDOMETHACIN. Minor upper GI problems, such as dyspepsia, commonly occur at any time. Healthcare providers should remain alert for ulceration and bleeding in patients treated with ODAN-INDOMETHACIN, even in the absence of previous GI tract symptoms. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration. For high risk patients, alternate therapies that do not involve NSAIDs should be considered. (see 7 WARNINGS AND PRECAUTIONS -7.1 Special Populations – 7.1.4 Geriatrics).
Patients should be informed about the signs and/or symptoms of serious GI toxicity and instructed to discontinue using ODAN-INDOMETHACIN and seek emergency medical attention if they experience any such symptoms. The utility of periodic laboratory monitoring has NOT been demonstrated, nor has it been adequately assessed. Most patients who develop a serious upper GI adverse event on NSAID therapy have no symptoms. Upper GI ulcers, gross bleeding or perforation, caused by NSAIDs, appear to occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. These trends continue, thus increasing the likelihood of developing a serious GI event at some time during the course of therapy. Even short-term therapy has its risks. The incidence of these complications increases with increasing dose.
There is no definitive evidence that the concomitant administration of histamine H2-receptor antagonists and/or antacids will either prevent the occurrence of gastrointestinal side effects or allow the continuation of indomethacin therapy when and if these adverse reactions appear.
Indomethacin suppositories should be given with caution to patients with any anal or rectal pathology. Caution should be taken if prescribing ODAN-INDOMETHACIN to patients with a prior history of
peptic / duodenal ulcer disease or gastrointestinal bleeding as these individuals have a greater than 10-fold higher risk for developing a GI bleed when taking a NSAID than patients with neither of these risk factors. Other risk factors for GI ulceration and bleeding include the following: Helicobacter pylori infection, increased age, prolonged use of NSAID therapy, excess alcohol intake, smoking, poor general health status or concomitant therapy with any of the following:
- Anti-coagulants (e.g. warfarin)
- Anti-platelet agents(e.g. ASA, clopidogrel)
- Oral corticosteroids (e.g. prednisone)
- Selective Serotonin Reuptake Inhibitors (SSRIs) (e.g. citalopram, fluoxetine, paroxetine, sertraline)
Studies in normal subjects with radioactive chromate tagged red blood cells indicate that large doses of indomethacin (50 mg four times a day) produce less fecal blood loss than average doses of acetylsalicylic acid (600 mg four times a day). Notwithstanding, indomethacin may cause single or multiple ulceration of the stomach, duodenum, or small and large intestine. There have been reports of severe bleeding and of perforation with a few fatalities. Patients may also develop gastrointestinal bleeding with no obvious ulcer formation. If gastrointestinal bleeding occurs, discontinue using the drug. In many patients with peptic ulceration, a history of previous ulcer was present or they were on concomitant steroids, salicylates or phenylbutazone. A possible potentiation of the ulcerogenic effect of these drugs cannot be ruled out at present. In some patients there was no history of a previous ulcer and other drugs were not being given. As a result of obvious or occult gastrointestinal bleeding some patients may manifest anemia. For this reason appropriate blood determinations are recommended periodically.
Genitourinary Tract
Some NSAIDs are known to cause persistent urinary symptoms (bladder pain, dysuria, and urinary frequency), hematuria or cystitis. The onset of these symptoms may occur at any time after the initiation of therapy with an NSAID. Some cases have become severe on continued treatment. Should urinary symptoms occur, treatment with indomethacin must be stopped immediately to obtain recovery. This should be done before any urological investigations or treatments are carried out.
Hematologic
NSAIDs inhibiting prostaglandin biosynthesis interfere with platelet function to varying degrees; patients who may be adversely affected by such an action, such as those on anti- coagulants or suffering from haemophilia or platelet disorders should be carefully observed when ODAN-INDOMETHACIN is administered.
Anti-coagulants:
Numerous studies have shown that the concomitant use of NSAIDs and anti- coagulants increases the risk of bleeding. Concurrent therapy of ODAN-INDOMETHACIN with warfarin requires close monitoring of the international normalized ratio (INR).
Even with therapeutic INR monitoring, increased bleeding may occur.
Anti-platelet Effects:
NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike acetylsalicylic acid (ASA), their effect on platelet function is quantitatively less, or of shorter duration, and is reversible. This effect usually disappears within 24 hours after discontinuation of
indomethacin. Indomethacin has been shown to prolong bleeding time (but within the normal range) in normal subjects without underlying coagulation defects.
ODAN-INDOMETHACIN and other NSAIDs have no proven efficacy as anti- platelet agents and should NOT be used as a substitute for ASA or other anti- platelet agents for prophylaxis of cardiovascular thromboembolic diseases. Anti- platelet therapies (e.g. ASA) should NOT be discontinued. There is some evidence that use of NSAIDs with ASA can markedly attenuate the cardioprotective effects of ASA. (see 9 DRUG INTERACTIONS - Drug-Drug Interactions - Acetylsalicylic Acid (ASA) or other NSAIDs)
Concomitant administration of ODAN-INDOMETHACIN with low dose ASA increases the risk of GI ulceration and associated complications.
Blood dyscrasias:
Blood dyscrasias (such as neutropenia, leukopenia, thrombocytopenia, aplastic anemia and agranulocytosis) associated with the use of NSAIDs are rare, but could occur with severe consequences.
Anemia is sometimes seen in patients receiving NSAIDs, including ODAN-INDOMETHACIN. This may be due to fluid retention, GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including ODAN-INDOMETHACIN, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia or blood loss.
Hepatic/Biliary/Pancreatic
As with other NSAIDs, borderline elevations of one or more liver function tests may occur in up to 15% of patients. Significant (3 times the upper limit of normal) elevations of ALT (SGPT) or AST (SGOT) occurred in controlled clinical trials in less than 1% of patients receiving therapy with NSAIDs. Liver function test abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of more severe hepatic reaction while on therapy with this drug. Severe hepatic reactions including jaundice and cases of fatal hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes, have been reported with nonsteroidal anti-inflammatory drugs.
Although such reactions are rare, if abnormal liver tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop (e.g jaundice), or if systemic manifestations occur (e.g. oesinophilia, rash, etc.), this drug should be discontinued.
If there is a need to prescribe this drug in the presence of impaired liver function, it must be done under strict observation.
Immune
In common with other anti-inflammatory drugs indomethacin may mask the usual signs of infection. The physician must be alert to this possibility to avoid undue delay in initiating appropriate treatment of the infection. Indomethacin should be used with caution in patients with existing, but controlled, infections.
Aseptic Meningitis:
In occasional cases, with some NSAIDs, the symptoms of aseptic meningitis (stiff neck, severe headaches, nausea and vomiting, fever or clouding of consciousness) have been observed. Patients with autoimmune disorders (systemic lupus erythematosus, mixed connective tissues diseases, etc.) seem to be predisposed. Therefore, in such patients, the physician must be vigilant to the development of this complication.
Monitoring and Laboratory Tests
Cardiovascular: Patients on long-term treatment with ODAN-INDOMETHACIN should have their blood pressure monitored regularly.
Hematology: Patients on long-term treatment with ODAN-INDOMETHACIN, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia or blood loss. Concurrent therapy with warfarin requires close monitoring of the international normalized ratio (INR).
Hepatic: During long-term therapy, liver function tests should be monitored periodically. If there is a need to prescribe this drug in the presence of impaired liver function, it must be done under strict observation.
Ophthalmic: Ophthalmic examination should be carried out at periodic intervals in any patient receiving this drug for extended periods of time.
Pregnancy: If ODAN-INDOMETHACIN is administered in the middle (approximately 20 weeks) to the end of the second trimester, it is recommended that pregnant women on ODAN-INDOMETHACIN be closely monitored for amniotic fluid volume since ODAN-INDOMETHACIN may result in reduction of amniotic fluid volume and even oligohydramnios (see Special Populations). ODAN-INDOMETHACIN is contraindicated for use in the third trimester of pregnancy.
Renal: During long-term therapy, kidney function and serum electrolytes should be monitored periodically. See 7 WARNINGS AND PRECAUTIONS – Renal.
Drug interactions: See 9 DRUG INTERACTIONS for other situations requiring monitoring.
Neurologic
Some patients may experience drowsiness, dizziness, vertigo, insomnia or depression with the use of indomethacin. If patients experience these side effects, they should exercise caution in carrying out activities that require alertness.
Headache may occur, usually early in treatment with indomethacin. If headache persists despite dosage reduction therapy, indomethacin should be discontinued.
Indomethacin should be used with caution in patients with epilepsy, or Parkinsonism, since it may, in some instances, aggravate these conditions.
Geriatric patients are more likely to develop adverse CNS effects, especially confusion, while taking indomethacin.
Occupational Hazards
Patients on indomethacin, who suffer from dizziness, light-headedness, or feelings of detachment, should be cautioned against operating motor vehicles or other machinery, climbing ladders, etc., if these symptoms are present.
Ophthalmologic
Blurred and/or diminished vision has been reported with the use of indomethacin and other NSAIDs. If such symptoms develop this drug should be discontinued and an ophthalmologic examination performed.
Corneal deposits and retinal disturbances, including those of the macula, have been reported in some patients with rheumatoid arthritis on prolonged therapy with indomethacin. Similar eye changes have been observed in some patients with this disease who have not received indomethacin.
Ophthalmic examination should be carried out at periodic intervals in any patient receiving this drug for extended periods of time.
Peri-Operative Considerations
See 2 CONTRAINDICATIONS.
Psychiatric
Indomethacin should be used with caution in patients with psychiatric disturbances, epilepsy, or Parkinsonism, since it may, in some instances, aggravate these conditions.
See also 7 WARNINGS AND PRECAUTIONS – Neurologic.
Renal
Long-term administration of nonsteroidal anti-inflammatory drugs to animals has resulted in renal papillary necrosis and other abnormal renal pathology. In humans, there have been reports of acute interstitial nephritis with hematuria, proteinuria, and occasionally nephrotic syndrome.
Renal insufficiency due to NSAID use is seen in patients with pre-renal conditions leading to reduction in renal blood flow or blood volume. Under these circumstances, renal prostaglandins help maintain renal perfusion and glomerular filtration rate (GFR). In these patients, administration of a NSAID may cause a reduction in prostaglandin synthesis leading to impaired renal function. Patients at greatest risk of this reaction are those with pre-existing renal insufficiency (GFR < 60 mL/min or 1 mL/s), dehydrated patients, patients on salt restricted diets, those with congestive heart failure, cirrhosis, liver dysfunction, taking angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, cyclosporin, diuretics, and those who are elderly. Serious or life-threatening renal failure has been reported in patients with normal or impaired renal function after short term therapy with NSAIDs. Even patients at risk who demonstrate the ability to tolerate a NSAID under stable conditions may decompensate during periods of added stress (e.g. dehydration due to gastroenteritis). Discontinuation of NSAIDs is usually followed by recovery to the pre-treatment state.
Caution should be used when initiating treatment with NSAIDs, such as ODAN-INDOMETHACIN, in patients with considerable dehydration. Such patients should be rehydrated prior to initiation of therapy. Caution is also recommended in patients with pre-existing kidney disease.
Indomethacin and its metabolites are eliminated primarily by the kidneys; therefore, the drug should be used with great caution in patients with impaired renal function. In these cases, utilization of lower doses of indomethacin should be considered and patients carefully monitored. To avoid excessive drug accumulation, a lower daily dosage may be necessary.
During long-term therapy kidney function should be monitored periodically.
Advanced Renal Disease: See 2 CONTRAINDICATIONS
Fluid and Electrolyte Balance: Use of NSAIDs, such as ODAN-INDOMETHACIN, can promote sodium retention in a dose-dependent manner, which can lead to fluid retention and edema, and consequences of increased blood pressure and exacerbation of congestive heart failure. Thus, caution should be exercised in prescribing ODAN-INDOMETHACIN in patients with a history of congestive heart failure, compromised cardiac function, hypertension, increased age or other conditions predisposing to fluid retention.
Use of NSAIDs, such as ODAN-INDOMETHACIN, can increase the risk of hyperkalemia, especially in patients with diabetes mellitus, renal failure, increased age, or those receiving concomitant therapy with adrenergic blockers, angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, cyclosporin, or some diuretics.
Electrolytes should be monitored periodically. See 2 CONTRAINDICATIONS
Reproductive Health: Female and Male Potential
See 7.1.1 Pregnant Women.
Fertility: The use of ODAN-INDOMETHACIN, as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. Therefore, in women who have difficulties conceiving, or who are undergoing investigation of infertility, withdrawal of ODAN-INDOMETHACIN should be considered.
Respiratory
ASA-induced asthma is an uncommon but very important indication of ASA and NSAID sensitivity. It occurs more frequently in patients with asthma who have nasal polyps.
Sensitivity/Resistance
Patients should be followed carefully to detect unusual manifestations of drug sensitivity, and since advancing years appear to increase the possibility of adverse reactions, indomethacin should be used with greater care in the elderly.
Anaphylactoid Reactions: As with NSAIDsin general, anaphylactoid reactions have occurred in patients without known prior exposure to ODAN-INDOMETHACIN. Inpost-marketing experience, rare cases of anaphylactic/ anaphylactoid reactions and angioedema have been reported in patients receiving indomethacin. ODAN-INDOMETHACIN should NOT be given to patients with the ASA-triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking ASA or other NSAIDs (see 2 CONTRAINDICATIONS).
ASA-Intolerance: ODAN-INDOMETHACIN should NOT be given to patients with complete or partial syndrome of ASA-intolerance (rhinosinusitis, urticaria/angioedema, nasal polyps, asthma) in whom asthma, anaphylaxis, urticaria/angioedema, rhinitis or other allergic manifestations are precipitated by ASA or other NSAIDs. Fatal anaphylactoid reactions have occurred in such individuals. As well, individuals with the above medical problems are at risk of a severe reaction even if they have taken NSAIDs in the past without any adverse reaction (see 2 CONTRAINDICATIONS).
Cross-sensitivity: Patients sensitive to one NSAID may be sensitive to any of the other NSAIDs as well.
Serious skin reactions: See 7 WARNINGS AND PRECAUTIONS - Skin
Skin
Serious skin reactions: Use of some NSAIDs, such as ODAN-INDOMETHACIN, have been associated with rare post-market cases of serious, fatal or otherwise life-
threatening skin reactions, including:
- drug reaction with eosinophilia and systemic symptoms (DRESS)
- Stevens-Johnson syndrome,
- toxic epidermal necrolysis,
- exfoliative dermatitis and
- erythema multiforme.
Patients appear to be at higher risk for these events early in the course of therapy, with the onset of cases usually occurring within the first month of treatment. These reactions may be reversible if the causative agent is discontinued, and appropriate treatment instituted. Patients should be advised that they should discontinue their NSAID at the first appearance of a skin rash, mucosal lesions or any other sign of hypersensitivity, and contact their physician immediately for assessment and advice, including which therapies to discontinue.
DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection, and eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.
7.1 Special Populations
7.1.1 Pregnant Women
ODAN-INDOMETHACIN is contraindicated for use during the third trimester of pregnancy because of risks of premature closure of the ductus arteriosus and the potential to prolong parturition (see 16 NON- CLINICAL TOXICOLOGY). Caution is recommended in prescribing ODAN-INDOMETHACIN during the first and second trimesters of pregnancy, particularly from the middle to end of the second trimester of pregnancy (onset at approximately 20 weeks) due to possible fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment or failure.
Published studies and post marketing reports describe maternal NSAID use at approximately 20 weeks gestation or later in pregnancy associated with fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment or failure. NSAIDs were shown to cause significant reduction in fetal urine production prior to reduction of amniotic fluid volume. There have also been a limited number of case reports of maternal NSAID use and neonatal renal dysfunction and renal impairment without oligohydramnios, some of which were irreversible, even after treatment discontinuation.
These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Complications of prolonged oligohydramnios may for example, include limb contractures and delayed lung maturation. In some post marketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.
If after careful consideration of the benefit-risk, NSAID treatment is considered necessary to be administered anywhere from the middle (onset at approximately 20 weeks) to the end of the second trimester of pregnancy, the use should be limited to the lowest effective dose and shortest duration possible. It is also recommended that ultrasound monitoring of amniotic fluid be considered if ODAN-INDOMETHACIN treatment extends beyond 48 hours and that NSAIDs treatment be discontinued if oligohydramnios occurs, followed by appropriate medical follow up.
Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo-fetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy.
In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-fetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenesis period.
7.1.2 Breast-feeding
Indomethacin is excreted in the milk of lactating mothers. Indomethacin is not recommended for use in nursing mothers. (See 2 CONTRAINDICATIONS).
7.1.3 Pediatrics
The drug should not be prescribed for children because safe conditions for use have not been established in those 15 years and younger. In a few cases of severe juvenile rheumatoid arthritis, where indomethacin was given along with other drugs, severe reactions, including fatalities, were reported. (See 2 CONTRAINDICATIONS).
7.1.4 Geriatrics
Patients older than 65 years and frail or debilitated patients are most susceptible to a variety of adverse reactions from NSAIDs; the incidence of these adverse reactions increases with dose and duration of treatment. In addition, these patients are less tolerant to ulceration and bleeding. Most reports of fatal GI events are in this population. Older patients are also at risk of lower œsophageal ulceration and
bleeding.
For such patients, consideration should be given to a starting dose lower than the one usually recommended, with individual adjustment when necessary and under close supervision (see 7 WARNINGS AND PRECAUTIONS).
Geriatric patients are more likely to develop adverse CNS effects, especially confusion, while taking indomethacin.
8 ADVERSE REACTIONS
8.1 Adverse Reaction Overview
The most common adverse reactions encountered with NSAIDs are gastrointestinal, of which peptic ulcer, with or without bleeding, is the most severe. Fatalities have occurred, particularly in the elderly.
The following local adverse reactions have been very commonly (> 10%) associated with the use of indomethacin suppositories:
- proctitis
- burning
- tenesmus
- rectal bleeding
- pain
- itching
- discomfort
8.2 Clinical Trial Adverse Reactions
Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.
The following table (Table 2) presents adverse reactions for indomethacin capsules. The incidence was obtained from 33 double-blind controlled clinical trials reported in the literature (1, 092 patients). The adverse reactions reported with indomethacin capsules may occur with the use of the suppositories.
Table 2: Most Common Clinical Trial Adverse Drug Reactions (3%-9% and >1%)
| Body System | Incidence 3-9% | Incidence > 1% |
| Gastrointestinal | Nausea with or without vomiting. Dyspepsia, (including indigestion, heartburn and epigastric pain) | Diarrhea, abdominal distress or pain, constipation |
| Body System | Incidence 3-9% | Incidence > 1% |
| Central Nervous System | Dizziness | Headache, vertigo, somnolence, depression, and fatigue (including malaise and listlessness) |
| Special Senses | None | Tinnitus |
8.3 Less Common Clinical Trial Adverse Reactions
Table 3: Less Common Clinical Trial Adverse Drug Reactions (<1%)
| Body System | Incidence < 1% |
| Gastrointestinal | Anorexia, bloating (includes distention), flatulence, peptic ulcer, gastroenteritis, rectal bleeding, proctitis, single and multiple ulcerations (including perforation and hemorrhage of the œsophagus, stomach, duodenum, or small and large intestine), intestinal ulceration associated with stenosis and obstruction, gastrointestinal bleeding without obvious ulcer formation and perforation of preexisting sigmoid lesions (diverticulum, carcinoma, etc.), development of ulcerative colitis and regional ileitis, ulcerative stomatitis, toxic hepatitis and jaundice (some fatal cases have been reported). |
| Central Nervous System | Anxiety (includes nervousness), muscle weakness, involuntary muscle movements, insomnia, hebetude, psychic disturbances (including psychotic episode), mental confusion, drowsiness, lightheadedness, syncope, paresthesia, aggravation of epilepsy and parkinsonism, depersonalization, coma, peripheral neuropathy, convulsions, dysarthria. |
| Dermatologic | Pruritus, rash; urticaria, petechiæ or ecchymosis, exfoliative dermatitis, erythema nodosum, loss of hair, Stevens Johnson syndrome, erythema multiforme, toxic epidermal necrolysis. |
| Cardiovascular | Hypertension, hypotension, tachycardia, chest pain, congestive heart failure, arrhythmia, palpitations |
| Special Senses | Ocular - corneal deposits and retinal disturbances including those of the macula have been reported in some patients on prolonged therapy with indomethacin, blurred vision, diplopia, hearing disturbances, deafness |
| Hematologic | Leukopenia, bone marrow depression, anemia secondary to obvious or occult gastrointestinal bleeding, aplastic anemia, hemolytic anemia, agranulocytosis, thrombocytopenic purpura, disseminated intravascular coagulation |
| Genitourinary | Hematuria, vaginal bleeding, proteinuria, nephrotic syndrome, interstitial nephritis, BUN elevation, renal insufficiency, including renal failure. |
| Hypersensitivity | Acute anaphylaxis, acute respiratory distress, rapid fall in blood pressure (resembling a shock-like state), angioedema, dyspnea, asthma, purpura, angiitis, pulmonary edema |
| Metabolic | Edema, weight gain, fluid retention, flushing or sweating, hyperglycemia, glycosuria, hyperkalemia |
| Miscellaneous | Epistaxis, breast changes (including enlargement and tenderness, or gynecomastia) |
8.5 Post-Market Adverse Reactions
Additional reports of serious adverse events temporally associated with ODAN-INDOMETHACIN during worldwide post-marketing experience are included below. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or clearly establish a causal relationship to ODAN-INDOMETHACIN exposure.
Local Adverse Reactions associated with
the use of suppositories:
Rectal irritation, tenesmus, rectal bleeding, pain, itching, proctitis, burning, discomfort
Cardiovascular: thrombophlebitis
Hematologic: leukemia
Skin and Subcutaneous Tissue Disorders: Photosensitivity reactions
9 DRUG INTERACTIONS
9.1 Serious Drug Interactions
9.3 Drug-Behaviour Interactions
Excess alcohol intake or smoking may increase the risk of gastrointestinal ulceration and bleeding. See 7 WARNINGS AND PRECAUTIONS, Gastrointestinal.
Patients on indomethacin, who suffer from dizziness, light-headedness, or feelings of detachment, should be cautioned against operating motor vehicles or other machinery, climbing ladders, etc., if these symptoms are present. See 7 WARNINGS AND PRECAUTIONS, Neurologic.
9.4 Drug-Drug Interactions
ASA or other NSAIDs: The use of indomethacin in addition to any other NSAID, including over-the- counter ones (such as ASA and ibuprofen) is not recommended due to the possibility of additive side effects and the absence of any evidence demonstrating synergistic benefits.
The exception is the use of low dose ASA for cardiovascular protection, when another NSAID is being used for its analgesic/anti-inflammatory effect, keeping in mind that combination NSAID therapy is associated with additive adverse reactions.
Some NSAIDs(e.g. ibuprofen) may interfere with the anti-platelet effects of low dose ASA, possibly by competing with ASA for access to the active site of cyclooxygenase-1.
Serious Drug Interactions
The combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage. See 9.4 Drug-Drug Interactions.
The use of indomethacin in conjunction with ASA or other salicylates is not recommended. Controlled clinical studies have shown that the combined use of indomethacin with ASA does not produce any greater therapeutic effect than the use of indomethacin alone. Furthermore, in one of these clinical studies, the incidence of gastrointestinal side effects was significantly increased with combined therapy.
In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of ASA/day decreases indomethacin blood levels approximately 20%.
The combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage. The coadministration of diflunisal and indomethacin results in an increase of about 30 to 35% in indomethacin plasma levels and a concomitant decrease in renal clearance of indomethacin and its conjugate. Therefore, indomethacin and diflunisal should not be used concomitantly.
Acetaminophen: Prolonged concurrent use of acetaminophen with an NSAID may increase the risk of adverse renal effects. It is recommended that patients be under close medical supervision while receiving such combined therapy.
Alcohol: Concurrent use with an NSAID may increase the risk of gastrointestinal side effects, including ulceration or hemorrhage.
Aminoglycosides: Administration of indomethacin to neonates (see 2 CONTRAINDICATIONS) being treated for a patent ductus has decreased the renal clearance and increased the plasma concentration of concurrently administered aminoglycoside antibiotics. Although not documented, similar effects may occur in other patients, leading to increased risk of toxicity. Adjustment of aminoglycoside dosage may be required.
Anticoagulants and Thrombolytic Agents: Indomethacin has been reported to potentiate the effects of coumarin- or indanedione-derivative anticoagulants.
Numerous studies have shown that the concomitant use of NSAIDs and anticoagulants increases the risk of GI adverse events such as ulceration and bleeding.
Inhibition of platelet aggregation by NSAIDs, and the possibility of NSAID-induced gastrointestinal ulceration or bleeding, maybe hazardous to patients receiving anticoagulant or thrombolytic therapy.
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function, concurrent therapy of indomethacin with warfarin requires close monitoring to be certain that no change in anticoagulant dosage is necessary.
Controlled clinical studies have shown that indomethacin did not influence the hypoprothrombinemia produced by the use of anticoagulants in patients and in normal subjects. However, when any additional drug, including indomethacin is added to the treatment of patients on anticoagulant therapy, the patient should be observed closely for alterations of the prothrombin time.
Antidiabetic Agents and Insulin: NSAIDs may increase the hypoglycemic effect of these medications because prostaglandins are directly involved in regulatory mechanisms of glucose metabolism and possibly because of displacement of the oral antidiabetic from serum proteins. Decreased blood glucose concentrations have been reported. Dosage adjustments of the antidiabetic agent may be necessary.
Antihypertensive Agents and Diuretics: NSAIDs may diminish the anti-hypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
Combinations of ACE inhibitors, angiotensin-II antagonists, or diuretics with NSAIDs might have an increased risk for acute renal failure and hyperkalemia. Blood pressure and renal function (including electrolytes) should be monitored more closely in this situation, as occasionally there can be a substantial increase in blood pressure.
In some patients, the administration of indomethacin can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics. Therefore, when indomethacin and diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
Indomethacin reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion. These facts should be considered when evaluating plasma renin activity in hypertensive patients.
Indomethacin may block the increase in plasma renin activity induced by butemide, furosemide and indapamide.
It has been reported that the addition of triamterene to a maintenance schedule of indomethacin resulted in reversible acute renal failure in two of four healthy volunteers. Indomethacin and triamterene should not be administered together.
Indomethacin and potassium-sparing diuretics each may be associated with increased serum potassium levels. The potential effects of indomethacin and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.
Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by indomethacin.
A decrease in the antihypertensive effect of beta-adrenergic receptor blocking agents by NSAIDs including indomethacin has been reported. Therefore, when using a beta-blocking agent to treat hypertension, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained.
Bone Marrow Depressants: Leukopenic and/or thrombocytopenic effects of these medications may be increased with concurrent or recent therapy if an NSAID causes the same effects. Dosage adjustment of the bone marrow depressant, if necessary, should be based on blood counts.
Concomitant use of indomethacin and pemetrexed may increase the risk of pemetrexed-associated myelosupression, renal, and GI toxicity. In patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. Indomethacin should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.
Colchicine: Concurrent use with an NSAID mayincrease the risk of gastrointestinal ulceration or hemorrhage.
Inhibition of platelet aggregation by NSAIDs, added to colchicine's effects on blood clotting mechanisms (colchicine may cause thrombocytopenia with chronic use and clotting defects, including disseminated intravascular coagulation, with overdose), may increase the risk of bleeding at sites other than the gastrointestinal tract.
Corticosteroids (Glucocorticoids & Prednisolone): Numerous studies have shown that the concomitant use of NSAIDs and oral glucocorticoids increases the risk of GI side effects such as ulceration and bleeding. This is especially the case in older (>65 years of age) individuals. However, concurrent use with a glucocorticoid or corticotropin in the treatment of arthritis may provide additional therapeutic benefit and permit reduction of glucocorticoid or corticotropin dosage.
Cyclosporine: Inhibition of renal prostaglandin activity by NSAIDs may increase the plasma concentration of cyclosporine and/or risk of cyclosporine-induced nephrotoxicity. Patients should be carefully monitored during concurrent use.
Digoxin: Indomethacin has been reported to increase digoxin concentrations in neonates being treated for patent ductus arteriosus. Presently, conflicting evidence exists for the clinical significance of digoxin- indomethacin interaction in man. While some studies have shown that indomethacin increases serum digoxin to levels high in the therapeutic range, others have shown that indomethacin did not alter the elimination half-life, systemic clearance or distribution of digoxin.
Increased monitoring is recommended when digoxin and NSAIDs are coadministered. Dosage adjustments of the digitalis glycoside may be necessary during and following concurrent NSAID therapy.
Lithium: Indomethacin 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady-state plasma lithium concentrations. This effect has been attributed to inhibition of prostaglandin synthesis. As a consequence, when indomethacin and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity (Read the product monograph for the appropriate lithium preparation before use of such concomitant therapy). In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment.
Methotrexate: Caution should be used if indomethacin is administered simultaneously with methotrexate. Indomethacin has been reported to decrease the tubular secretion of methotrexate and to potentiate toxicity.
Nephrotoxic Medications and Gold Compounds: The risk of adverse renal effects may also be increased when an NSAID is used concurrently with other nephrotoxic medications, possibly including gold compounds (although NSAIDs and gold compounds are commonly used concurrently in the treatment of arthritis).
Platelet Aggregation Inhibitors: Concurrent use with an NSAID may increase the risk of bleeding because of additive inhibition of platelet aggregation, as well as the potential for NSAID-induced gastrointestinal ulceration or hemorrhage.
Concurrent use of sulfinpyrazone with NSAIDs may also increase the risk of gastrointestinal ulceration or hemorrhage.
Potassium Supplements: Concurrent use with an NSAID may increase the risk of gastrointestinal side effects, including ulceration or hemorrhage.
Probenecid: When indomethacin is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased. Therefore, a lower total daily dosage of indomethacin may produce a therapeutic effect. When increases in the dose of indomethacin are made under these circumstances, they should be made cautiously and in small increments.
Protein-Bound Agents: Indomethacin, like other NSAIDs in general is highly protein-bound, and therefore the potential exists for drug interactions to occur when it is co-administered with other protein-bound agents.
The potential therefore exists for the displacement of a drug from its plasma protein binding sites by NSAIDs which are tightly protein-bound.
Competition for the same binding sites on plasma proteins may be at least partly responsible for some interactions of NSAIDs with other highly bound drugs. However, other mechanisms such as decreased metabolism or decreased urinary elimination may also be involved.
The clinical significance of these interactions is of greatest importance with drugs that have a small therapeutic window. For example, methotrexate maybe displaced from its binding protein sites by NSAIDs.
Selective Serotonin Reuptake Inhibitors (SSRIs): Concomitant administration of NSAIDs and SSRIs may increase the risk of gastrointestinal ulceration and bleeding (see 7 WARNINGS AND PRECAUTIONS - Gastrointestinal).
Tacrolimus: Inhibition of renal prostaglandin activity by NSAIDs may increase the nephrotoxic effect of tacrolimus. Patients should be monitored for necessary dose adjustment and for signs of worsening renal function.
Quinolone anti-bacterials: There have been isolated reports of convulsions which may have been due to concomitant use of quinolones and NSAIDs. Patients should be observed for adjustment of dose if required.
Valproic Acid: Valproic acid may cause hypoprothrombinemia and may inhibit platelet aggregation. Concurrent use with an NSAID may increase the risk of bleeding because of additive interferences with platelet function and/or the potential occurrence of NSAID-induced gastrointestinal ulceration or hemorrhage.
Zidovudine: Indomethacin may competitively inhibit hepatic glucuronidation and decrease the clearance of zidovudine, possibly leading to potentiation of zidovudine toxicity. Indomethacin toxicity may also be increased. Concurrent use of the two medications should be avoided.
9.5 Drug-Food Interactions
Interactions with food have not been established.
9.6 Drug-Herb Interactions
Interactions with herbal products have not been established.
9.7 Drug-Laboratory Test Interactions
False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients.
False 5-HIAA concentration values may be measured via the Goldenberg modification of Underfriend's method because indomethacin metabolites are structurally similar to 5-HIAA.
10 CLINICAL PHARMACOLOGY
10.1 Mechanism of Action
Indomethacin is a nonsteroidal drug that has anti-inflammatory, analgesic, and antipyretic activity. It has a unique chemical structure, which differentiates it from the salicylates, corticosteroids, phenylbutazone-like compounds and colchicine. Unlike corticosteroids, it has no effect on pituitary or adrenal function.
As with other nonsteroidal anti-inflammatory agents, the exact mechanism of action of indomethacin has not been fully elucidated but has been attributed to the inhibition of prostaglandin synthesis.
Although indomethacin does not alter the course of the underlying disease, it has been found effective to relieve pain, reduce fever, swelling and tenderness, and increase mobility in patients with rheumatic disorders of the types listed.
10.2 Pharmacodynamics
Anti-Inflammatory Action
Two methods were used to demonstrate the anti-inflammatory activity of indomethacin – the inhibition of granuloma formation induced by subcutaneous implantation of cotton pellets into rats and the inhibition of edema induced by subplantar injection of carrageenan into rats.
Results of the inhibition of granuloma formation by orally administered drug indicate that indomethacin is approximately 85 times more potent than phenylbutazone and approximately 4 times more potent than hydrocortisone. Results of the inhibition of carrageenan-induced edema indicate the same order of potency, which is as follows:
indomethacin>hydrocortisone>phenylbutazone>aspirin
Indomethacin is effective in the absence of the adrenals. Administration of indomethacin did not affect the size of the adrenals or the thymus unlike anti-inflammatory steroids. Also, it did not slow down gain in body weight. The anti-inflammatory effect of combinations of indomethacin and a steroid was greater than comparable doses of either drug alone.
Results from an experiment on adjuvant-induced polyarthritis in rats indicate that indomethacin is more effective than phenylbutazone or acetylsalicylic acid in suppressing the delayed manifestations of disseminated arthritis.
Antipyretic Activity
The antipyretic activity of indomethacin was demonstratedin ratsand rabbits in which fever was induced by injection of bacterial pyrogen. Results show that indomethacin is more potent than aminopyrine, aspirin, or phenylbutazone in preventing fever.
Clinical observations in patients with a varietyof febrile conditions confirm the antipyretic activityof indomethacin. However, indomethacin should not be used simply as an antipyretic agent.
Analgesic Activity
The analgesic activity of indomethacin was demonstratedin laboratorytests designed to detect mild analgesic activity. Results indicate that indomethacin is more potent than acetylsalicylic acid or aminopyrine. However, indomethacin should not be used simply as ananalgesic agent.
10.3 Pharmacokinetics
In man, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL at about 2 hours following single oral doses of 25 and 50 mg, respectively. Ninety percent of the orally-administered indomethacin is absorbed within 4 hours. Indomethacinis eliminated via renal excretion and biliary excretion. Indomethacin undergoes appreciable enterohepatic circulation. The mean half-life of indomethacin is estimatedto be about 4.5 hours. With a typical therapeutic regimenof 25 or 50 mg t.i.d., the steady-state plasma concentrations of indomethacin are on average 1.4 times those following the first dose.
Indomethacin exists in the plasma as the parent drug and its desmethyl, desbenzoyl, and desmethyldesbenzoyl metabolites, all in the unconjugated form. About 60% of an oral dosage is recovered in urine as drug and metabolites (26% as indomethacin and its glucuronide), and 33% is recovered in feces (1.5% as indomethacin).
About 90% of indomethacin is bound to protein in plasma over the expected range of therapeutic plasma concentration.
Following oral administration, bioavailability is virtually 100% with 90% of a single dose being absorbed within 4 hours. The bioavailability of the drug following rectal administration of suppositories has generally been reported to be comparable to or slightly less than that following oral administration of the drug. The bioavailability of the drug following rectal administration of suppositories has been reported to be about 80-90%.
Bioavailability studies were performed using normal human volunteers on both the 50 mg and 100 mg indomethacin suppository formulations. Eachformulation wasmeasured and comparedto either the 50 mg or 100 mg Indocid® suppository (Merck, Sharp & Dohme). The results are summarizedas follows:
Odan Indocid®
50 mg Formulation 1 x 50 mg 1 x 50 mg Bioavailability
AUC(0-t) (ng.hr/mL) 7251.75 7195.54 101.35% AUC(0-infinity) (ng.hr/mL) 7557.73 7454.65 102.06% Cmax (ng/mL) 1510.64 1473.45 102.24% Tmax (hours) 1.73 1.94
T½ (hours) 7.89 7.62
Kel (hours-1) 0.103 0.099
The mean plasma indomethacin levels (shown below) show that both 50 mg formulations have similar absorption and elimination patterns, which peak at approximately 2 hours.
Similar patterns can be seen for the 100 mg formulation (see below). Both the Odan 100 mg suppository and the Indocid® 100 mg suppository peak at approximately 2 hours and each have an apparent half-life of 8 hours.
The results of the comparison of the 100 mg ODAN-INDOMETHACIN suppository and the 100 mg Indocid® suppository are as follows:
100 mg Formulation
Odan
1 x 100 mg
Indocid® 1 x 100 mg
Bioavailability
AUC(0-t) (ng.hr/mL)
15127.42
14900.72
101.76%
AUC(0-infinity) (ng.hr/mL) 15536.53 15213.07 102.27% Cmax (ng/mL) 2988.25 2936.91 102.36% Tmax (hours) 1.88 1.94 T1/2 (hours) 8.13 7.54 Kel (hours-1) 0.091 0.097
As can be seen from above, both the Odan 50 mg Odan Indomethacin suppository and the Odan 100 mg ODAN-INDOMETHACIN suppository are bioequivalent to the corresponding 50 mg or 100 mg Indocid® suppository.
11 STORAGE, STABILITY AND DISPOSAL
ODAN-INDOMETHACIN suppositories should be stored at room temperature, between 15 and 30°C.
12 SPECIAL HANDLING INSTRUCTIONS
Not applicable.
PART II: SCIENTIFIC INFORMATION
13 PHARMACEUTICAL INFORMATION
Drug Substance
Proper Name: indomethacin USP
Chemical Name: 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl
Molecular Formula and molecular mass: C19H16C1NO4, 357.79g/ mol
Structural Formula:
CH3O
CH2COOH
N CH3
O
Cl
Physiochemical Properties: Indomethacin occurs as a pale yellow to yellow-tan crystalline powder, with a slight odour and is practically insoluble in water and sparingly soluble in alcohol. Indomethacin has a pKa of 4.5, a melting point of about 162 C and exhibits polymorphism. Indomethacin is sensitive to light and is unstable in alkaline solution.
14 CLINICAL TRIALS
14.3 Comparative Bioavailability Studies
Two bioavailability studies were performed using human volunteers. The rate and extent of absorption after a single rectal administration of Indocid® 50 mg suppositories and ODAN-INDOMETHACIN 50 mg suppositories, and Indocid® 100 mg suppositories and ODAN-INDOMETHACIN 100 mg suppositories, were measured and compared. The results can be summarized as follows:
Summary Tables of the Comparative Bioavailability Data
Indomethacin
(50 mg suppositories)
From measured data
| f s (%) A | |||
* Reference: Indocid® 50 mg suppository (Merck, Sharp & Dohme, PQ, Canada) ** These are arithmetic means (CV%)
A Calculated using geometric means according to the formula: e (Odan (A)-Indocid®(B)) x 100% The Tmax and T1/2 parameters are expressed as the arithmetic means (CV%) only.
Indomethacin
(100 mg suppositories)
From measured data
| o s | f (%) A | |
* Reference: Indocid® 100 mg suppository (Merck, Sharp & Dohme, PQ, Canada) ** These are arithmetic means (CV %)
A Calculated using geometric means according to the formula: e (Odan (A)-Indocid®(B)) x 100%
The Tmax and T1/2 parameters are expressed as the arithmetic means (CV %) only.
| Parameter | Geometric Mean Ratio o Arithmetic Mean (CV %) Mean | ||
| Test | Reference* Test/Reference | ||
| AUCT (ng·hr/mL) | 7044.48 7251.75 (24.15) | 6974.39 101% 7195.54 (27.91) | |
| AUCI (ng·hr/mL) | 7405.66 7557.73 (22.85) | 7259.02 102% 7454.65 (26.81) | |
| Cmax (ng/mL) | 1465.57 1510.64 (23.00) | 1436.55 102% 1473.45 (22.44) | |
| Tmax (hours)** | 1.73 (22.53) | 1.94 (30.74) --- | |
| T1/2 (hours)** | 7.89 (37.88) | 7.62 (31.04) --- | |
| Kel (hour -1)** | 0.103 (47.210) | 0.099 (27.965) --- | |
Parameter
Geometric Mean Ratio Arithmetic Mean (CV %) Mean | |||
| Test | Reference* Test/Reference | ||
| AUCT (ng·hr/mL) | 14913.17 15127.42 (20.35) | 14617.87 102% 14900.72 (21.51) | |
| AUCI (ng·hr/mL) | 15214.44 15536.53 (20.29) | 14913.17 102% 15213.07 (20.94) | |
| Cmax (ng/mL) | 2921.93 2988.25 (23.02) | 2864.07 102% 2936.91 (21.96) | |
| Tmax (hours)** | 1.88 (43.96) | 1.94 (28.79) --- | |
| T1/2 (hours)** | 8.13 (25.27) | 7.54 (24.16) --- | |
| Kel (hour -1)** | 0.091 (26.978) | 0.097 (24.824) --- | |
15 MICROBIOLOGY
Not applicable.
16 NON-CLINICAL TOXICOLOGY
Toxicity studies of indomethacin have been performed on many animal species including mice, rats, rabbits and dogs. The doses tolerated by man were higher than those tolerated by the experimental animals.
GI ulcerations, the main toxic effect of indomethacin, usually occurred within 2 weeks when more than 5 mg/kg/day were given. Other toxic effects reported were cellular infiltration of the kidney and liver in rats and renal amyloidosis and papillary necrosis in mice when 2-5 mg/kg/day were given.
Reproduction studies in rats and mice indicated that indomethacin is not teratogenic at doses up to 4 mg/kg/day. But, at higher doses of 5-15 mg/kg/day, maternal toxicity increased fetal resorption and fetal malformations were reported. In rats, indomethacin delays parturition.
The acute oral toxicity of indomethacin sustained-release pellets (LD50 = 912 mg/kg) is similar to that of indomethacin base compounds (LD50 = 849 mg/kg) in female mice based on 24-hour mortality. The LD50 of indomethacin base compounds based on a 14-day mortality in mice is 50 mg/kg.
Indomethacin has been found to delay parturition in rats. This effect has been described with other NSAIDs which inhibit prostaglandin synthesis.
In rats, 4 mg/kg/day given during the last three days of gestation caused some maternal and fetal deaths. An increased incidence of neuronal necrosis in the diencephalon in the live-born fetuses was observed. At 2 mg/kg/day no increase in neuronal necrosis was observed as compared to the control groups.
